Kevin L Winthrop1,2, Huifeng Yun3,4, Jeffrey R Curtis3,4, Maria I Danila3, Lang Chen3, Benjamin Chan5, Ben Ehst6, Fenglong Xie3. 1. Divisions of Infectious Diseases, Ophthalmology, and Public Health and Preventive Medicine, Oregon Health and Science University. 2. Center for Health Systems Effectiveness, Oregon Health and Science University. 3. University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology. 4. University of Alabama at Birmingham, Department of Epidemiology. 5. Oregon Health and Science University, Department of Emergency Medicine. 6. Oregon Health and Science University, Department of Dermatology.
Abstract
BACKGROUND: The risk for cardiovascular events associated with systemic therapies for psoriasis, including biologics, is unclear. METHODS: We used administrative data from Medicare 2006 through 2011 to identify psoriasis patients who initiated systemic treatments. We estimated incidence rates of hospitalized myocardial infarction, stroke, and a composite cardiovascular disease outcome, adjusting for potentially confounding factors. RESULTS: There were 28,878 initiations of psoriasis treatments. Rates of myocardial infarction were highest for methotrexate (10.32/1000 patient-years, 95%CI 8.55-12.46) and numerically lower for biologics. Patterns were similar for stroke and the composite cardiovascular disease outcome. After multivariable adjustment, there were no significant differences between systemic therapies for any of the outcomes studied. CONCLUSIONS: In this cohort of predominantly older psoriasis patients, there was no elevated nor protective risk of cardiovascular or stroke events associated with systemic therapies for psoriasis compared to conventional treatments.
BACKGROUND: The risk for cardiovascular events associated with systemic therapies for psoriasis, including biologics, is unclear. METHODS: We used administrative data from Medicare 2006 through 2011 to identify psoriasis patients who initiated systemic treatments. We estimated incidence rates of hospitalized myocardial infarction, stroke, and a composite cardiovascular disease outcome, adjusting for potentially confounding factors. RESULTS: There were 28,878 initiations of psoriasis treatments. Rates of myocardial infarction were highest for methotrexate (10.32/1000 patient-years, 95%CI 8.55-12.46) and numerically lower for biologics. Patterns were similar for stroke and the composite cardiovascular disease outcome. After multivariable adjustment, there were no significant differences between systemic therapies for any of the outcomes studied. CONCLUSIONS: In this cohort of predominantly older psoriasis patients, there was no elevated nor protective risk of cardiovascular or stroke events associated with systemic therapies for psoriasis compared to conventional treatments.
Authors: Kory K Parsi; Elizabeth A Brezinski; Tzu-Chun Lin; Chin-Shang Li; April W Armstrong Journal: J Am Acad Dermatol Date: 2011-11-12 Impact factor: 11.527
Authors: Camille Roubille; Vincent Richer; Tara Starnino; Collette McCourt; Alexandra McFarlane; Patrick Fleming; Stephanie Siu; John Kraft; Charles Lynde; Janet Pope; Wayne Gulliver; Stephanie Keeling; Jan Dutz; Louis Bessette; Robert Bissonnette; Boulos Haraoui Journal: J Rheumatol Date: 2015-07-15 Impact factor: 4.666
Authors: Christianne L Roumie; Edward Mitchel; Patricia S Gideon; Cristina Varas-Lorenzo; Jordi Castellsague; Marie R Griffin Journal: Pharmacoepidemiol Drug Saf Date: 2008-01 Impact factor: 2.890